
IEA says it stands ready to tap emergency oil stocks, OPEC sees no need
The west's energy watchdog said on Friday it was ready to release oil stocks should the market experience shortages following Israel's attack on Iran, drawing criticism from rival OPEC which said the statement would only create fear in the market.
The International Energy Agency, representing oil consumers, and the Organization of the Petroleum Exporting Countries, representing some of the world's top oil producers, have in recent years clashed on global oil demand trajectories and the pace of the energy transition.
The IEA's head Fatih Birol said that while the oil market was well supplied, the agency would be ready to act if needed, adding that the agency's oil security system held US1.2 billion barrels of oil in strategic and emergency reserves.
OPEC Secretary General Haitham Al Ghais criticized Birol's statement, saying it 'raises false alarms and projects a sense of market fear through repeating the unnecessary need to potentially use oil emergency stocks.'
He said there were no developments in supply or market dynamics that 'warrant unnecessary measures.'
Oil prices jumped sharply after Israel launched a barrage of strikes across Iran on Friday, saying it had attacked nuclear facilities and missile factories and killed a swathe of military commanders in what could be a prolonged operation to prevent Tehran building an atomic weapon.
Oil prices were trading seven per cent higher, their biggest daily spike since 2022 when Russia invaded Ukraine.
The United States and its allies, in coordination with the IEA, last tapped emergency oil stocks in early 2022 after the Russian invasion of Ukraine, a decision that OPEC heavily criticized at the time.
While Israel has stopped short of targeting Iran's energy facilities, market participants are wary the situation may escalate further leading to damage to energy infrastructure in Iran or its neighbors, as well as a blockade of the Strait of Hormuz.
In September 2019, Iran-backed Houthi militias in Yemen launched a drone attack on Saudi Aramco's 2222.SE Abqaiq oil processing plant, knocking 5.7 million bpd of Saudi oil production offline and sending the oil market into a frenzy.
Iran's diplomatic relations with its Gulf neighbors Saudi Arabia and the United Arab Emirates have improved significantly since that attack, though there are still some concerns in the region of a repeat of the Abqaiq scenario.
'Oil has already spiked ... and its ultimate landing point will likely hinge on whether Iran revives the 2019 playbook and targets tankers, pipelines, and key energy facilities across the region,' RBC Capital Markets analyst Helima Croft said in a note following the Israeli attack.
(Reporting by Ashitha Shivaprasad in Bengaluru and Ahmad Ghaddar in London, Editing by Louise Heavens and Susan Fenton)
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
36 minutes ago
- Globe and Mail
Strategy Announces $4.2 Billion Stock Sales Agreement
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Strategy ( (MSTR)) has shared an announcement. On July 31, 2025, Strategy announced a sales agreement with several agents to issue and sell shares of its Variable Rate Series A Perpetual Stretch Preferred Stock, with an aggregate offering price of up to $4.2 billion. The company plans to use the proceeds for general corporate purposes, including the acquisition of Bitcoin and working capital. The sales will be conducted as an 'at the market offering' and are subject to terms and conditions outlined in the sales agreement. This move is part of Strategy's broader strategy to leverage its position in the digital asset market and enhance its financial flexibility. The most recent analyst rating on (MSTR) stock is a Buy with a $392.00 price target. To see the full list of analyst forecasts on Strategy stock, see the MSTR Stock Forecast page. Spark's Take on MSTR Stock According to Spark, TipRanks' AI Analyst, MSTR is a Neutral. The overall stock score of 48 reflects significant financial and valuation challenges, with high leverage and negative earnings outweighing positive strategic initiatives and Bitcoin-focused capital strategies. Despite a strong strategic focus on cryptocurrency and recent successful capital raising, the financial instability and legal risks pose substantial concerns. To see Spark's full report on MSTR stock, click here. More about Strategy MicroStrategy Incorporated, doing business as Strategy, is a publicly traded company recognized as the world's first and largest Bitcoin Treasury Company. It has adopted Bitcoin as its primary treasury reserve asset and strategically accumulates Bitcoin through equity and debt financings, as well as cash flows from operations. The company also provides AI-powered enterprise analytics software, integrating analytics expertise with digital asset growth, positioning itself as a leader in both the digital asset and enterprise analytics sectors. Average Trading Volume: 12,259,375 Technical Sentiment Signal: Buy Current Market Cap: $111.9B See more data about MSTR stock on TipRanks' Stock Analysis page.


CBC
2 hours ago
- CBC
Lawyer breaks down legal fight over Trump's tariffs
U.S. President Donald Trump's use of emergency powers to impose across-the-board tariffs on trading partners came under sharp questioning from federal appellate court judges. Robert Glasgow, partner with McCarthy Tetrault LLP, talks about the legal challenges to Trump's authority to impose tariffs.


Globe and Mail
2 hours ago
- Globe and Mail
AstraZeneca's AZD3427 Study: A Potential Game-Changer for Heart Failure and Pulmonary Hypertension
AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca, in collaboration with Parexel International, is conducting a Phase IIb study titled A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Due to Left Heart Disease (WHO Group 2). The study aims to assess the efficacy of AZD3427 in reducing pulmonary vascular resistance in patients with heart failure and pulmonary hypertension over 24 weeks, highlighting its potential significance in treating these conditions. The intervention being tested is AZD3427, administered as a subcutaneous injection. It is designed to target pulmonary hypertension by reducing vascular resistance, with the study evaluating three different dose levels of the drug. The study follows a randomized, parallel assignment model with triple masking, involving participants, care providers, and investigators. Its primary purpose is treatment-focused, aiming to determine the optimal dosing strategy for AZD3427. The study began on April 24, 2023, with an estimated completion date in July 2025. These timelines are crucial for tracking the progress and potential market introduction of AZD3427. The outcome of this study could significantly impact AstraZeneca's market position, potentially boosting its stock performance if results are positive. Investors will be keenly watching for updates, especially in the context of competitive treatments for heart failure and pulmonary hypertension. The study is ongoing, with further details available on the ClinicalTrials portal.